Table 4.

Clinical trials of PD-L1 combination therapy with conventional cytotoxic chemotherapeutics targeting TNBC patients.

Drugs	Tested Patients	Combination with	Phase	Trial
Pembrolizumab	Neoadjuvant treatment for TNBC	Cyclophosphamide Paclitaxel Nab-paclitaxel Doxorubicin Carboplatin	I	NCT02622074;
Pembrolizumab	Metastatic TNBC (mTNBC)	Gemcitabine Carboplatin	II	NCT02755272
Pembrolizumab	Neoadjuvant and Adjuvant treatment for TNBC	Doxorubicin Epirubicin Cyclophosphamide Placebo Carboplatin Paclitaxel	III	NCT03036488
Pembrolizumab	Metastatic TNBC (mTNBC)	Capecitabine Paclitaxel	I/II	NCT02734290
Pembrolizumab	Metastatic TNBC (mTNBC)	Eribulin	Ib/II	NCT02513472;
Pembrolizumab	Metastatic TNBC (mTNBC)	Radiotherapy	II	NCT02730130
Pembrolizumab	Metastatic TNBC (mTNBC)	Cyclophosphamide	II	NCT02768701
Pembrolizumab	Metastatic TNBC (mTNBC)	Paclitaxel Gemcitabine Carboplatin Nab-paclitaxel	II	NCT02819518;
Durvalumab	Locally Advanced TNBC	Paclitaxe Epirubicin Cyclophosphamide	II	NCT03356860
Durvalumab		Nab-paclitaxel Epirubicin Cyclophosphamide	II	NCT02685059
Durvalumab	Clinical Stage I-III TNBC	Nab-paclitaxel Dose-dense doxorubicin/cyclophosphamide (ddAC)	I/II	NCT02489448
Durvalumab	mTNBC patients	Paclitaxel	I/II	NCT02628132
Durvalumab	First-line chemotherapy TNBC patients	Nab-paclitaxel + carboplatin + tremelimmab+Gemcitabine + carboplatin + tremelimumab	Ib	NCT02658214
Durvalumab	Metastatic TNBC (mTNBC)	Carboplatin Gemcitabine Hydrochloride Nab-paclitaxel Neoantigen vaccine	II	NCT03606967
Durvalumab	mTNBC patent	Carboplatin Paclitaxel Oleclumab (MEDI9447; anti-CD73)	I/II	NCT03616886
Atezolizumab	Advanced TNBC patient	Paclitaxel	Ib	NCT01633970
Atezolizumab	mTNBC patient	Nab-Paclitaxel Placebo	III	NCT02425891
Atezolizumab	Neoadjuvant treatment for TNBC	Anthracyclin, Abraxane Carboplatin, M PDL3280A	III	NCT02620280
Nivolumab	mTNBC patient	Cisplatin Romidepsin	I/II	NCT02393794